the New England Section of the American Urological Association
Search Meeting Site Only
Annual Meeting Home
Past & Future Meetings: NEAUA

Back to 2011 Program

Comparing Post-operative Complication rates between Neoadjuvant Chemotherapy and Chemotherapy Na´ve Patients who undergo Cystectomy for Bladder Cancer
Jack W Lambert, III, Stephen Riggs, Matthew Ingham, Bethany Barone

EVMS, Norfolk, VA

Although it may appear implicit that patients who receive neoadjuvant chemotherapy (NC) for bladder cancer would have higher complication rates post-operatively, there has been sparse literature published on this subject. Our single institution study compares complication rates between NC and chemotherapy (CT) na´ve patients who underwent radical cystectomy (RC).
We performed a retrospective review from our bladder cancer database of 208 patients and we included any patient from 2004-2011 who underwent cystectomy for bladder cancer. 13 patients were excluded from analysis because they died prior to cystectomy. Immediate post-operative and 90 day complications were recorded for all patients.
Interestingly, 60.5% of patients in the NC group and 71.3% in chemotherapy na´ve group had at least one complication. The Clavien-Dindo classification scores were 2.39 and 2.55 for the NC and CT na´ve groups, respectively. There was a total of 347 post-operative and 90 day complications in 208 patients, or 1.73 complications per patient.

NeoadjuvantCT naive
Number of patients50158
Age (years)65.768.1
EBL (mL)1214898
Length of stay (days)1011.7
Follow up (months)20.827.5
OR time (minutes)422402
ASA score2.782.77
Pre-operative albumin3.874.01

Patients who underwent NC had a 10.8% lower post-operative complication rate than CT na´ve patients. Therefore, in our single institution study NC does not confer an increased complication risk and the potential risk for complications should not deter urologists from the pursuing this option for patients.

Back to 2011 Program


© 2024 New England Section of the American Urological Association. All Rights Reserved. Privacy Policy.